EUVIMEDEUVIMED entdecken
Kommentar

In RA, use of systemic glucocorticoids ≥5 mg/d (prednisolone-equivalent) was linked to MACE at 8.7 y

Ami Schattner

Annals of Internal Medicine · 2023

DOI: 10.7326/j23-0082 ↗

Kurz gefasst

Kommentar in der Zeitschrift Annals of Internal Medicine, 2023. Verfasst von Ami Schattner. Beteiligte Einrichtung: Hebrew University-Hadassah, Jerusalem, Israel (A.S.). Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SOURCE CITATION: So H, Lam TO, Meng H, et al. Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study. Ann Rheum Dis. 2023;82:1387-1393.37487608.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsHumansGlucocorticoidsPrednisolone

Substanzen

GlucocorticoidsPrednisoloneAntirheumatic Agents

Autor:innen und Institutionen

  • Hebrew University-Hadassah, Jerusalem, Israel (A.S.).

Zitieren

APA

Schattner, A. (2023). In RA, use of systemic glucocorticoids ≥5 mg/d (prednisolone-equivalent) was linked to MACE at 8.7 y. Annals of Internal Medicine. https://doi.org/10.7326/j23-0082

Vancouver

Schattner A. In RA, use of systemic glucocorticoids ≥5 mg/d (prednisolone-equivalent) was linked to MACE at 8.7 y. Annals of Internal Medicine. 2023. doi:10.7326/j23-0082

BibTeX
@article{Schattner2023,
  author = {Schattner, Ami},
  title = {In RA, use of systemic glucocorticoids ≥5 mg/d (prednisolone-equivalent) was linked to MACE at 8.7 y},
  journal = {Annals of Internal Medicine},
  year = {2023},
  doi = {10.7326/j23-0082}
}
Kostenlos starten →